Since its foundation in 2001, ReLIA Biotech has been at the forefront of research in point of care testing technologies, with its primary research and development centre located in Silicon Valley, California. Currently, it holds its Asian Pacific headquarters at the Shekou Free Trade Zone, Shenzhen, as well as large scale production and R&D centers in Shenzhen and Jiangsu.
Under the guidance of Dr. Willian J. Rutter, our companys founder, ReLIA has adhered to a diligent attitude towards research. We mold modern developments into technological advancement/systems, which promote rapid diagnostic services and improve the health and wellbeing of patients whilst simultaneously reducing medical costs.
Currently, the company focuses on two categories of rapid detection systems: The multi-functional immunoassay system and immunofluorescence detection system. Both of these systems cover the detection of biomarkers for cardiovascular, acute kidney injury and inflammatory related conditions.